Guolin Ye

Foshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2025

Development and validation of an online prognostic risk stratification tool to assist decisions on perioperative chemotherapy for men with luminal early breast cancer.

Development and validation of an online prognostic risk stratification tool to assist decisions on perioperative chemotherapy for men with luminal early breast cancer.

Journal: Breast cancer research : BCR

Published: October 13, 2025

Multiparametric MRI-based longitudinal-radiomics analysis for early prediction of treatment response of breast cancers to neoadjuvant chemotherapy.

Multiparametric MRI-based longitudinal-radiomics analysis for early prediction of treatment response of breast cancers to neoadjuvant chemotherapy.

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Published: August 27, 2025

Comparison of male breast cancer in China and the US: a real-world cohort study.

Comparison of male breast cancer in China and the US: a real-world cohort study.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: May 28, 2025

Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment.

Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment.

Journal: Journal of cancer research and clinical oncology

Published: September 28, 2024

ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.

ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.

Journal: Acta pharmaceutica Sinica. B

Published: August 20, 2024

The features of male breast cancer in China: A real-world study.

The features of male breast cancer in China: A real-world study.

Journal: Breast (Edinburgh, Scotland)

Published: May 09, 2024

Differential Response to Cisplatin between Co-cultured Cells and Pure Cultured Cells Based on Single-cell RNA Sequencing of Three-dimensional-cultured Breast Cancer Cells.

Differential Response to Cisplatin between Co-cultured Cells and Pure Cultured Cells Based on Single-cell RNA Sequencing of Three-dimensional-cultured Breast Cancer Cells.

Journal: Frontiers in bioscience (Landmark edition)

Published: May 09, 2024

Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

Journal: Gland surgery

Published: January 29, 2024

Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints.

Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints.

Journal: Frontiers in immunology

Published: November 24, 2023

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study.

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study.

Journal: EClinicalMedicine

Published: December 10, 2022

Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis.

Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis.

Journal: Medicine

Published: August 10, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026